Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $707.00 Price Target at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price cut by analysts at Royal Bank Of Canada from $762.00 to $707.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 13.62% from the stock’s previous close.

A number of other research analysts have also recently weighed in on REGN. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $810.91.

Regeneron Pharmaceuticals Trading Down 10.9%

Shares of NASDAQ:REGN traded down $75.98 during trading hours on Monday, hitting $622.27. 1,009,300 shares of the company’s stock traded hands, compared to its average volume of 753,718. The business has a fifty day moving average price of $744.69 and a 200-day moving average price of $746.09. The firm has a market capitalization of $65.79 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 1.55 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the prior year, the business earned $8.22 EPS. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post 37.1 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in REGN. WPG Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $29,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. Institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Regeneron’s phase 3 melanoma trial for fianlimab missed its main goal, weakening confidence in a high-profile pipeline asset and contributing to analyst downgrades. Reuters article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on REGN but cut its price target to $700 from $900, signaling a more cautious valuation view. Tickerreport article
• Neutral Sentiment: Leerink Partners also reaffirmed a market perform rating and lowered its target to $641 from $792, reflecting reduced expectations after the trial setback. Benzinga article
• Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel antibody-Helicon conjugates, a pipeline-expanding deal that could eventually generate significant milestone payments and royalties. Yahoo Finance article

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.